Xu M, Bhatt DK, Yeung CK, Claw KG, Chaudhry AS, Gaedigk A, Pearce RE, Broeckel U, Gaedigk R, Nickerson DA, et al
Global prevalence estimates typically range from 0.31%, though reports vary widely -from 0.001% to over 4%- largely due to methodological and diagnostic differences across studies [9]
Training at or above 70% of 1RM has been shown to be particularly effective in preserving lean mass during caloric deficits (Shea et al., 2011
Rachel Sorvig, a spokesperson for Zepbound and Mounjaro manufacturer Eli Lilly, said in a statement that users should talk to their health care provider about dosage and duration needs. Studies have shown that people typically regain a substantial amount of weight within a year of stopping GLP-1 medications, and that many people who quit ultimately go back on the drugs